Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
REGULATORY
Ultomiris Caught by CEA Rule despite Intractable Disease Indication: Chuikyo
Japan’s key reimbursement policy panel on August 28 agreed to apply a cost-effectiveness assessment (CEA) to Alexion Pharmaceuticals’ Ultomiris (ravulizumab) despite the drug being indicated only for paroxysmal nocturnal hemoglobinuria, a state-designated intractable disease. Ultomiris, the US company’s Soliris (eculizumab)…
To read the full story
Related Article
- Ultomiris Faces 4.3% Price Cut under CEA Scheme
May 12, 2021
- Ultomiris Now Braced for Price Cut as Chuikyo OKs CEA Results
April 15, 2021
- Rozlytrek, Onpattro and Many More to Join NHI Price List on Sept. 4
August 28, 2019
REGULATORY
- Keytruda SC Tops New NHI Listing Round with 75 Billion Yen Sales Outlook
November 9, 2026
- Japan Set to Prioritize Pharma in Growth Strategy Action Plan
November 9, 2026
- Japan to Delist 657 Drugs, Including ActHIB and Alofisel
November 9, 2026
- Kisunla Price Cut Set at 3.93% under Japan’s CEA Scheme
November 6, 2026
- Japan Nudged to Probe Wide Gaps in Biosimilar Uptake
November 6, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…